GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/37y30N9
via IFTTT